Cannabis Public Position and Policy Papers
presented for reference without specific endorsements
Workplace Strategies: Risk of Impairment from Cannabis
Canadian Center for Occupational Health and Safety 02/ 2018
Impairment in the workplace can have severe consequences. There are many sources of impairment such as fatigue, life stresses, use of drugs (over the counter, prescription, illicit), consumption of alcohol, etc. This White Paper discusses the implications associated with the use of cannabis for both therapeutic and recreational purposes.
LESSONS FROM AROUND AMERICA
TAADAS January 2018
The 2017 National Cannabis Summit held August 28-30 in Denver, CO, provided a structure for an objective national discussion of policies and regulatory approaches to enhance public health and safety, improve prevention and treatment, and to respond to changing cannabis policies.
From Prohibition to Progress: A status Report on Marijuana Legalization
Drug Policy Alliance, Jan 2018
Marijuana arrests are down. Arrests from marijuana in all legal marijuana states and Washington, D.C. have plummeted, saving states hundreds of millions of dollars and sparing thousands of people from being branded with lifelong criminal records.
Attorney General’s Memorandum on Federal Marijuana Enforcement: Possible Impacts
Congressional Research Service 01/10/2018
Generally, the Obama-era guidance documents afforded state and local government officials, businesses, and individuals some measure of reassurance that they could facilitate or participate in state-authorized marijuana cultivation, distribution, sale, and possession activities without much concern of federal interference, despite the fact that federal law generally prohibits most conduct involving marijuana.
The Legalization of Marijuana in Colorado: The Impact
RMHIDTA October 2017
The Rocky Mountain HIDTA's ultimate mission is to facilitate cooperation and coordination among federal, state and local drug enforcement efforts to enhance combating the drug trafficking problem locally, regionally and nationally.
H.R.3391 - Medical Marijuana Research Act of 2017
Introduced in House (07/25/2017)
This bill amends the Controlled Substances Act to establish a new, separate registration process to facilitate research with marijuana for medical purposes. The Drug Enforcement Administration must register: (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research.
The Marijuana Policy Gap and the Path Forward
Congressional Research Service 3/10/2017
As of March 2017, nearly 90% of the states, as well as Puerto Rico and the District of Columbia, allow for the medical use of marijuana in some capacity. Also, eight states and the District of Columbia now allow for some recreational use of marijuana. These developments have spurred a number of questions regarding their potential implications for federal law enforcement activities and for the nation’s drug policies as a whole.
Hemp as an Agricultural Commodity
Congressional Research Service 3/10/2017
Industrial hemp is an agricultural commodity that is cultivated for use in the production of a wide range of products, including foods and beverages, cosmetics and personal care products, and nutritional supplements, as well as fabrics and textiles, yarns and spun fibers, paper, construction and insulation materials, and other manufactured goods.
Defining “Industrial Hemp”: A Fact Sheet
Congressional research Service 01/23/2017
Under current U.S. drug policy, all cannabis varieties, including industrial hemp, are considered Schedule I controlled substances under the Controlled Substances Act (CSA),3 and the U.S. Drug Enforcement Administration (DEA) continues to control and regulate hemp production.
in Portion and Dosage
An assessment of physical and pharmacokinetic relationships in marijuana production and consumption in Colorado by Colorado Department of Revenue 8/10/2015
This report was commissioned under Colorado HB 14-1361. The Colorado Department of Revenue retained the University of Colorado, Leeds School of Business, Business Research Division, in partnership with the Marijuana Policy Group, and BBC Research & Consulting, to produce an unbiased and scientific report for the purpose of rulemaking by Colorado stakeholders.
Medical Marijuana Laws and Mental Health in the United States
Centre for Economic Performance
Paper No 1546 May 2018
We contribute to the ongoing discussion by evaluating the impact of the staggered introduction and extension of medical marijuana laws across US states on self-reported mental health. Our main analysis is based on BRFSS survey data from more than six million respondents between 1993 and 2015. On average, we find that medical marijuana laws lead to a reduction in the self-reported number of days with mental health problems. Reductions are largest for individuals with high propensities to consume marijuana for medical